These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11304652)

  • 21. Determination of diethylcarbamazine, an antifilarial drug, in human urine by 1H-NMR spectroscopy.
    Jaroszewski JW; Berenstein D; Sløk FA; Simonsen PE; Agger MK
    J Pharm Biomed Anal; 1996 Mar; 14(5):543-9. PubMed ID: 8738183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide.
    Neuvonen PJ; Kivistö K; Hirvisalo EL
    Br J Clin Pharmacol; 1988 Feb; 25(2):229-33. PubMed ID: 3358884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration.
    Laine K; Kivistö KT; Pelttari S; Neuvonen PJ
    Pharmacol Toxicol; 1996 Nov; 79(5):270-3. PubMed ID: 8936562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of activated charcoal on absorption of tolbutamide and valproate in man.
    Neuvonen PJ; Kannisto H; Hirvisalo EL
    Eur J Clin Pharmacol; 1983; 24(2):243-6. PubMed ID: 6404636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral activated charcoal and dapsone elimination.
    Neuvonen PJ; Elonen E; Mattila MJ
    Clin Pharmacol Ther; 1980 Jun; 27(6):823-7. PubMed ID: 7379451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effects of multiple-dose activated charcoal on the absorption of orally administered salicylate in a simulated toxic ingestion model.
    Barone JA; Raia JJ; Huang YC
    Ann Emerg Med; 1988 Jan; 17(1):34-7. PubMed ID: 3337412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of activated charcoal and magnesium citrate in the prevention of aspirin absorption in humans.
    Easom JM; Caraccio TR; Lovejoy FH
    Clin Pharm; 1982; 1(2):154-6. PubMed ID: 7185512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man.
    Neuvonen PJ; Elfving SM; Elonen E
    Eur J Clin Pharmacol; 1978 May; 13(3):213-8. PubMed ID: 668776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diethylcarbamazine in the treatment of Bancroft's filariasis].
    Dreyer G; Norões J
    Rev Soc Bras Med Trop; 1997; 30(3):229-40. PubMed ID: 9273570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of delayed administration of activated charcoal on nortriptyline absorption.
    Dawling S; Crome P; Braithwaite R
    Eur J Clin Pharmacol; 1978 Dec; 14(6):445-7. PubMed ID: 738352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated charcoal-carboxymethylcellulose gel formulation as an antidotal agent for orally ingested aspirin.
    Mathur LK; Jaffe JM; Colaizzi JL; Moriarty RW
    Am J Hosp Pharm; 1976 Jul; 33(7):717-9. PubMed ID: 941924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of oral charcoal and urine pH on sotalol pharmacokinetics.
    Kärkkäinen S; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):441-6. PubMed ID: 6092287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of purgatives on antidotal efficacy of oral activated charcoal.
    Neuvonen PJ; Olkkola KT
    Hum Toxicol; 1986 Jul; 5(4):255-63. PubMed ID: 3733116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated oral doses of activated charcoal and the clearance of tobramycin, a non-absorbable drug.
    Watson WA; Jenkins TC; Velasquez N; Schentag JJ
    J Toxicol Clin Toxicol; 1987; 25(3):171-84. PubMed ID: 3612896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration.
    Laine K; Kivistö KT; Laakso I; Neuvonen PJ
    Br J Clin Pharmacol; 1997 Jan; 43(1):29-33. PubMed ID: 9056049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of the effect of repeated doses of oral activated charcoal on salicylate elimination.
    Ho JL; Tierney MG; Dickinson GE
    J Clin Pharmacol; 1989 Apr; 29(4):366-9. PubMed ID: 2723125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of sorbitol and activated charcoal on serum theophylline concentrations after slow-release theophylline.
    Goldberg MJ; Spector R; Park GD; Johnson GF; Roberts P
    Clin Pharmacol Ther; 1987 Jan; 41(1):108-11. PubMed ID: 3802699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of activated charcoal on the absorption of amiodarone.
    Kivistö KT; Neuvonen PJ
    Hum Exp Toxicol; 1991 Sep; 10(5):327-9. PubMed ID: 1683545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of activated charcoal in a simulated poisoning with acetaminophen: a new loading dose for N-acetylcysteine?
    Chamberlain JM; Gorman RL; Oderda GM; Klein-Schwartz W; Klein BL
    Ann Emerg Med; 1993 Sep; 22(9):1398-402. PubMed ID: 8363113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of chloroquine absorption by activated charcoal.
    Neuvonen PJ; Kivistö KT; Laine K; Pyykkö K
    Hum Exp Toxicol; 1992 Mar; 11(2):117-20. PubMed ID: 1349217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.